Company news

Immix Biopharma, Inc. news in 2025

Immix Biopharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

December 9, 2025

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

December 7, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

December 7, 2025

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

November 12, 2025

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

November 3, 2025

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

October 14, 2025

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

October 6, 2025

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

October 1, 2025

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

September 18, 2025

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

September 11, 2025

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

September 8, 2025

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

August 25, 2025

Immix Biopharma Announces Other Serious Diseases Strategy

August 6, 2025

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

July 11, 2025

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

July 7, 2025

Immix Biopharma Attends FDA CEO Forum in Washington DC

June 6, 2025

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

June 3, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

May 23, 2025

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

May 22, 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

May 21, 2025

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

April 23, 2025

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

February 9, 2025

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

January 6, 2025

Decks in 2025